NovImmune raised €27M in a Series D+ round in Jan 2016. The company is based in Plan-les-Ouates, Switzerland. Data as of 7 Aug 2026.
Reported in EUR — no conversion. €27M
Confidence is the weaker of amount-FX and source evidence (the cascade rule). See methodology.
No investors disclosed for this round.
